Conflicted Confidence: Academic Oncologists’ Views on Multiplex Pharmacogenomic Testing
Menée par questionnaire auprès de 160 médecins du Dana-Farber Cancer Institute, cette étude analyse leurs attitudes vis-à-vis du recours à des tests de génomique somatique pour orienter leurs choix thérapeutiques
Multiplex somatic genomic tests simultaneously evaluate multiple pharmacogenomic loci in the tumor genome to identify variants that may drive the growth, invasion, and/or metastatic spread of cancer and that may serve as targets for currently available or experimental therapies. In recent years, a growing number of multiplex somatic genomic panels with the capacity to examine tens to hundreds of genetic loci have become available to oncology care providers through research studies and commercial sources, in large part as a
result of the improved time and cost efficiencies afforded by multiplex testing using next-generation sequencing technologies...
Journal of Clinical Oncology , éditorial en libre accès, 2014